Vnitr Lek 2013, 59(2):96-98

Měnící se přístup k léčbě AL-amyloidózy - editorial

L. Elbl
Kardiologická ambulance Brno - Lesná, vedoucí pracoviště prof. MUDr. Lubomír Elbl, CSc.

Received: January 15, 2013; Published: February 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Elbl L. Měnící se přístup k léčbě AL-amyloidózy - editorial. Vnitr Lek. 2013;59(2):96-98.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ščudla V, Pika T. Současné možnosti léčby systémové AL amyloidózy. Vnitř Lék 2009; 55: (Suppl. 1): 77-87.
    2. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583-596. Go to original source... Go to PubMed...
    3. Nihoyannopoulos P, Dawson D. Restrictive cardiomyopathies. Eur J Echocardiography 2009; 10: 23-33. Go to original source...
    4. Garcia-Pavia P, Tome-Esteban MT, Rapezzi C. Amyloidosis. Also a Heart Disease. Res Esp Cardiol 2011; 64: 797-808. Go to original source...
    5. Ščudla V, Pika T. Monoklonální gamapathie nejistého významu ve světle současných poznatků. Klin Biochem Metab 2009; 17: 62-71.
    6. Adam Z, Krejčí M, Neubauer J et al. Mnohočetný myelom. Postgraduální medicína 2011; 5: 492-503.
    7. Sher T, Hayman SR, Gertz MA. Treatment of Primary Systemic Amyloidosis (AL): Role of Intensive and Standard Therapy. Clin Adv Hematol Oncol 2012; 10: 644-651.
    8. Roy V. Autologous stem cell transplant for Al amyloidosis. Bone Marrow Res 2012; 2012: 238961. Go to original source... Go to PubMed...
    9. DePasquale E, Nasir K, Jacoby D. Outcomes of adults with restrictive cardiomyopathy post heart transplantation. J Heart Lung Transplant 2012; 31: 1269-1275. Go to original source... Go to PubMed...
    10. Nohria A. Should we avoid heart transplantation in cardiomyopathy due to radiotherapy/chemotherapy or amyloidosis? The devil is in te details. J Heart Lung Transplant 2012; 31: 1253-1256. Go to original source... Go to PubMed...
    11. Alloni A, Pellegrini C, Ragni T et al. Heart transplantation in patients with amyloidosis: single-center experience. Transplant Proc 2004; 36: 643-644. Go to original source... Go to PubMed...
    12. Dubrey SW, Burke MM, Hawkins PN et al. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Transplant 2004; 23: 1142-1153. Go to original source... Go to PubMed...
    13. Mignot A, Varnous S, Redonnet M et al. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Arch Cardiovasc Dis 2008; 101: 523-532. Go to original source... Go to PubMed...
    14. Roig E, Almenar L, Gonzalez-Vilchez F et al. Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. Am J Transplant 2009; 9: 1414-1419. Go to original source... Go to PubMed...
    15. Estep JD, Bhimaraj A, Reyes-Cordero AM et al. Heart transplantation and end-stage cardiac amyloidosis: a review and approach to evaluation and management. Methodist Debakey Cardiovasc J 2012; 8: 8-16. Go to original source... Go to PubMed...
    16. Oliveira GH, Hardaway BW, Kucheryavaya AY et al. Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. J Heart Lung Transplant 2012; 31: 805-810. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.